ArticleScientific reports2023
Propolis-loaded nanostructured lipid carriers halt breast cancer progression through miRNA-223 related pathways: an in-vitro/in-vivo experiment.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Evaluation of the synergistic and antagonistic antibacterial effects of pulsed electromagnetic fields combined with ciprofloxacin and nanochitosan.Scientific reports · 2026Article
- French Propolis Caffeic Acid Derivatives Protect Skeletal Muscle from Oxidative Damages.Biomolecules · 2026Article
- Nanostructured Lipid Carriers as Physicochemical Modulators of Complex Natural Extracts: Release Behavior and Bile-Induced Remodeling in Biorelevant Media.Molecules (Basel, Switzerland) · 2026Article
- Improving cisplatin chemotherapy in vivo by niosomal propolis and chrysin as nanoadjuvants.Medical oncology (Northwood, London, England) · 2025Article
- Potential Therapeutic Actions of Flavonoids Present in Propolis That Modulate Vascular Endothelial Growth Factor Signaling to Regulate Angiogenesis.Phytotherapy research : PTR · 2025Review
- Formulation and evaluation of polymeric nanoparticles to improve in vivo chemotherapeutic efficacy of mangiferin against breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Anticancer Phytochemical Delivery: Advances, Challenges, and Future Prospects.Pharmaceutics · 2025Review
- Therapeutic Potential of Propolis in Preclinical Models of Cancer and Infectious Diseases: A Review.International journal of molecular sciences · 2025Review
- Phospholipid-based nanolipid carriers for dual kinase inhibitors in triple-negative breast cancer.Nanomedicine (London, England) · 2025Article
- Development and evaluation of the rivaroxaban loaded nanostructured lipid carriers for improved oral bioavailability and safety.Scientific reports · 2025Article
- Recent advances in nano vehicles encapsulating cinnamic acid and its derivatives as promising anticancer agents.RSC advances · 2025Review
- Chemical composition of Egyptian propolis and studying its antimicrobial activity and synergistic action with honey against some multidrug-resistant uropathogens.Scientific reports · 2025Article
- EnhancedPreventive nutrition and food science · 2025Article
- Propolis-Based Nanostructured Lipid Carrier of α-Mangostin for Promoting Diabetic Wound Healing in Alloxan-Induced Mice.Journal of inflammation research · 2025Article
- Leveraging nanostructured lipid carriers to enhance targeted delivery and efficacy in breast cancer therapy: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Review
- A Comprehensive Review of Nanoparticles: From Classification to Application and Toxicity.Molecules (Basel, Switzerland) · 2024Review
- Review
- New insights of propolis nanoformulation and its therapeutic potential in human diseases.ADMET & DMPK · 2024Review
- Plant-Derived Nanocellulose with Antibacterial Activity for Wound Healing Dressing.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most frequent malignant tumor in women is breast cancer, and its incidence has been rising every year. Propolis has been used for its antibacterial, antifungal, and anti-inflammatory properties. The present study aimed to examine the effect of the Egyptian Propolis Extract (ProE) and its improved targeting using nanostructured lipid carriers (ProE-NLC) in Ehrlich Ascites Carcinoma (EAC) bearing mice, the common animal model for mammary tumors. EAC mice were treated either with 5-fluorouracil (5-FU), ProE, ProE-NLC, or a combination of ProE-NLC and 5-FU. Their effect on different inflammatory, angiogenic, proliferation and apoptotic markers, as well as miR-223, was examined. ProE and ProE-NLC have shown potential anti-breast cancer activity through multiple interrelated mechanisms including, the elevation of antioxidant levels, suppression of angiogenesis, inflammatory and mTOR pathways, and induction of the apoptotic pathway. All of which is a function of increased miRNA-223 expression. The efficiency of propolis was enhanced when loaded in nanostructured lipid carriers, increasing the effectiveness of the chemotherapeutic agent 5-FU. In conclusion, this study is the first to develop propolis-loaded NLC for breast cancer targeting and to recommend propolis as an antitumor agent against breast cancer or as an adjuvant treatment with chemotherapeutic agents to enhance their antitumor activity and decrease their side effects. Tumor targeting by ProE-NLC should be considered as a future therapeutic perspective in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.